Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer.

Related Articles

Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer.

BMJ Case Rep. 2016 Aug 18;2016:

Authors: van der Woude SO, van Laarhoven HW

Abstract
Ramucirumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) pathway, in combination with paclitaxel is becoming part of standard second-line systemic therapy for advanced oesophagogastric cancer, based on the results of the REGARD and RAINBOW trials. Common well-known side effects of VEGF pathway inhibitors are hypertension and infusion-related reactions. Here, we describe hypertension as the predominant feature of an infusion-related reaction in 2 patients with metastasised oesophagogastric carcinoma treated with ramucirumab and paclitaxel as second-line treatment and propose possible explanations of this side effect previously undescribed for ramucirumab.

PMID: 27539134 [PubMed - indexed for MEDLINE]

} http://ift.tt/2m71FqC


http://ift.tt/2m7r97v